Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Am J Psychiatry ; 155(8): 1064-73, 1998 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9699695

RESUMEN

OBJECTIVE: Intersubject averaging of structural magnetic resonance (MR) images has been infrequently used as a means to study group differences in cerebral structure throughout the brain. In the present study, the authors used linear intersubject averaging of structural MR images to evaluate the validity and utility of this technique and to extend previous research, conducted using a different approach to image averaging, in which reduction in thalamic size and abnormalities in perithalamic white matter tracts in the brains of schizophrenic patients were reported by Andreasen et al. METHOD: A 1.5-T MR scanner was used to obtain high-resolution, whole brain T1-weighted structural MR images for an age-matched sample of 25 schizophrenic patients and 25 normal control subjects. A "bounding box" procedure was used to create a single "averaged" brain for the schizophrenic group and for the control group. Differences in signal intensity between the two average brains were examined on a pixel-wise basis through use of one-tailed effect size maps. RESULTS: Effect size maps revealed widespread patchy signal intensity differences between the two groups in both cortical and periventricular areas, including major white matter tracts. The signal intensity differences were consistent with cortical thinning/sulcal widening and ventricular enlargement. No differences were found within thalamus or in immediately surrounding white matter. Effect size maps for differences (schizophrenic minus normal subjects) had only small values. CONCLUSIONS: These results are consistent with diffuse structural brain abnormalities of both gray and white matter in schizophrenic populations such as the one in this study.


Asunto(s)
Encéfalo/anatomía & histología , Imagen por Resonancia Magnética/estadística & datos numéricos , Esquizofrenia/diagnóstico , Adulto , Atrofia , Encéfalo/patología , Ventrículos Cerebrales/anatomía & histología , Ventrículos Cerebrales/patología , Líquido Cefalorraquídeo , Humanos , Procesamiento de Imagen Asistido por Computador/estadística & datos numéricos , Masculino , Escalas de Valoración Psiquiátrica , Reproducibilidad de los Resultados , Esquizofrenia/patología , Tálamo/anatomía & histología , Tálamo/patología
2.
Am J Psychiatry ; 151(5): 681-6, 1994 May.
Artículo en Inglés | MEDLINE | ID: mdl-8166309

RESUMEN

OBJECTIVE: Positron emission tomography and the fluorodeoxyglucose (FDG) method were used to determine the brain's metabolic response to neuroleptic challenge in a normal, disease-free state. METHOD: FDG measurements were obtained before and 12 hours after administration of 5 mg of haloperidol to 12 young normal men. These values were compared with test-retest FDG measures obtained from nine normal male control subjects who received no drug intervention. RESULTS: After haloperidol administration, the haloperidol subjects showed significantly lower glucose utilization in the neocortex, limbic cortex, thalamus, and caudate nucleus but not in the putamen or cerebellum. After adjustment for global effects, significant reductions were still evident in the frontal, occipital, and anterior cingulate cortex, whereas the putamen and cerebellum showed significant increases. CONCLUSIONS: This study, measuring the brain's metabolic response to acute receptor blockade, is a first step in the development of an assay of CNS pharmacological activity. By determining the response to neuroleptic challenge in a normal state, the study establishes a comparison group for determining response to challenge in various psychiatric conditions.


Asunto(s)
Encéfalo/metabolismo , Glucosa/metabolismo , Haloperidol/farmacología , Adulto , Encéfalo/diagnóstico por imagen , Encéfalo/efectos de los fármacos , Cerebelo/efectos de los fármacos , Cerebelo/metabolismo , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Desoxiglucosa/análogos & derivados , Desoxiglucosa/metabolismo , Fluorodesoxiglucosa F18 , Humanos , Sistema Límbico/efectos de los fármacos , Sistema Límbico/metabolismo , Masculino , Trastornos Mentales/diagnóstico , Trastornos Mentales/metabolismo , Putamen/efectos de los fármacos , Putamen/metabolismo , Tálamo/efectos de los fármacos , Tálamo/metabolismo , Tomografía Computarizada de Emisión
3.
Am J Psychiatry ; 143(7): 912-4, 1986 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-3013033

RESUMEN

Preclinical and clinical observations suggest that enhancement of prostaglandin activity inhibits catecholamine release and may have antidyskinetic effects. A double-blind therapeutic trial with prostaglandin precursor essential fatty acids was conducted in 16 patients with tardive dyskinesia. No beneficial effects were seen.


Asunto(s)
Discinesia Inducida por Medicamentos/tratamiento farmacológico , Ácidos Linolénicos/uso terapéutico , Ensayos Clínicos como Asunto , Método Doble Ciego , Discinesia Inducida por Medicamentos/metabolismo , Humanos , Ácidos Linolénicos/administración & dosificación , Ácidos Linolénicos/metabolismo , Masculino , Persona de Mediana Edad , Prostaglandinas E/metabolismo , Ácido gammalinolénico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA